Simulations Plus (NASDAQ:SLP) posted its earnings results on Sunday. The technology company reported $0.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.01, MarketWatch Earnings reports. Simulations Plus had a net margin of 22.96% and a return on equity of 24.44%.
Simulations Plus stock traded down $8.28 on Tuesday, hitting $71.05. 23,687 shares of the stock traded hands, compared to its average volume of 287,831. The firm has a market cap of $1.42 billion, a P/E ratio of 152.38, a price-to-earnings-growth ratio of 7.63 and a beta of -0.17. The business’s fifty day simple moving average is $65.06 and its 200 day simple moving average is $65.43. Simulations Plus has a 1 year low of $26.00 and a 1 year high of $83.78.
In other Simulations Plus news, Director Walter S. Woltosz sold 24,000 shares of the business’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $68.95, for a total transaction of $1,654,800.00. Following the completion of the sale, the director now directly owns 4,707,359 shares in the company, valued at approximately $324,572,403.05. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David L. Ralph sold 5,000 shares of the business’s stock in a transaction dated Monday, November 30th. The shares were sold at an average price of $55.65, for a total value of $278,250.00. Following the sale, the director now owns 16,581 shares of the company’s stock, valued at $922,732.65. The disclosure for this sale can be found here. Insiders have sold 64,881 shares of company stock valued at $4,347,992 over the last 90 days. Corporate insiders own 31.57% of the company’s stock.
Several research firms have recently issued reports on SLP. TheStreet upgraded shares of Simulations Plus from a “c+” rating to a “b” rating in a research note on Friday. Raymond James began coverage on shares of Simulations Plus in a research note on Friday, October 16th. They issued an “outperform” rating and a $95.00 target price for the company. BidaskClub upgraded shares of Simulations Plus from a “hold” rating to a “buy” rating in a research note on Wednesday, December 23rd. Oppenheimer boosted their price target on shares of Simulations Plus from $79.00 to $85.00 in a report on Tuesday. Finally, Zacks Investment Research downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Thursday, November 19th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $81.60.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.
Further Reading: Circuit Breakers
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.